

ASX RELEASE

8 April 2019

Securities to be released from Voluntary Escrow

Noxopharm Limited (“**NOX**” or the “**Company**”) (ASX: NOX) advises that in accordance with ASX Listing Rule 3.10A, the following securities are due for release from voluntary escrow:

Security Description	Number	Date of Release
Unlisted Ordinary Shares	31,027,568	8 May 2019
Unlisted Options, exercise price of \$0.30, expiry 28 February 2021	12,075,000	8 May 2019

These securities are held by related parties of Mr Graham Kelly, the founder and Managing Director of NOX.

The aforesaid Ordinary Shares being released from escrow (representing approximately 25.40% of the Company’s shares on issue) are not currently quoted on the ASX and as such quotation of these shares will be sought.

David Franks
P: +61 2 9299 9690
E: David.Franks@automicgroup.com.au

ABOUT NOXOPHARM LIMITED

Noxopharm is an Australian drug development company with offices in Sydney, New York and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy and chemotherapy. Veyonda® (previously known as NOX66) is the first pipeline product in clinical trials.